{"i": ["incretin - based", "GLP - 1RA", "sulfonylurea", "sulfonylureas", "GLP - 1RA ( liraglutide ) to metformin", "liraglutide", "basal insulin ( insulin detemir )", "metformin \u00b1 sulfonylurea", "metformin", "insulin detemir to metformin + liraglutide", "basal insulin ( detemir )", "Liraglutide", "continuation without insulin detemir", "continue unchanged metformin + liraglutide", "metformin + liraglutide", "insulin", "liraglutide to metformin .", "metformin .", "liraglutide + metformin", "\u03b1 - glucosidase inhibitors", "exenatide or continuation of basal insulin only", "placebo", "Insulin detemir", "insulin detemir", "metformin + liraglutide .", "basal insulin", "sulfonylureas and thiazolidinediones", "Metformin", "Glucagon - like peptide 1 receptor agonists ( GLP - 1RAs )", "GLP - 1RAs", "placebo - controlled", "insulin detemir added to metformin + liraglutide", "insulin glargine", "exenatide", "Basal Insulin", "exenatide ) to insulin", "dipeptidyl peptidase - 4 inhibitors", "metformin and sulfonylurea"], "o": ["serious AEs ( SAEs", "AEs", "glycemic efficacy and weight loss", "AEs of increased lipase", "minor hypoglycemia rates", "Mean weight", "minor hypoglycemic episodes", "Hypoglycemic episodes", "hypoglycemia risks", "median serum lipase", "ETDs", "hypoglycemia rates", "initial weight loss", "weight gain", "type 2 diabetes duration", "glycemic control , substantial weight loss", "Self - measured plasma glucose levels", "mean A1C", "A1C and FPG values", "glycated hemoglobin ( A1C ) levels", "mean self - measured FPG", "weight reductions", "free fatty acids", "gastrointestinal symptoms", "efficacy and safety", "lipase levels", "A1C levels", "pancreatitis", "calcitonin level", "A1C change", "A1C (%)", "major hypoglycemic episodes", "chronic pancreatitis", "Heart rate", "Minor hypoglycemic episodes", "minor hypoglycemia", "mean FPG", "major hypoglycemic event", "hypoglycemia", "major hypoglycemia", "weight loss", "A1C", "A1C with no weight increase and no hypoglycemia", "lipase ( or amylase ) levels", "acute pancreatitis", "serum lipids", "A1C reduction", "prescribed insulin detemir doses", "lipid levels", "glycemic control", "seven - point blood glucose profiles", "A1C reductions", "FPG", "systolic blood pressure", "low hypoglycemia rate .", "median serum lipase levels", "gastrointestinal adverse events .", "postprandial values", "A1C target", "hypoglycemia risk", "lipase", "percentage of participants reaching A1C < 7 and \u2264 6 . 5 %, FPG , postprandial plasma glucose from self - measured seven - point glucose profiles , weight , blood pressure , lipids , and percentage of participants reaching the composite end point of A1C < 7 % with no weight gain or hypoglycemia", "SAEs", "weight gain and no hypoglycemia", "major hypoglycemic events", "adverse events ( AEs ) and hypoglycemic episodes .", "blood glucose level", "risk of minor hypoglycemia .", "weight reduction", "incidence of confirmed minor hypoglycemia"]}